Curaleaf: Analysts Expect Q2 Revenue To Meet Low End Of Guidance

Curaleaf Holdings (CSE: CURA) announced that they will be reporting their second quarter financials after the market closes on August 9.

Analysts have a consensus C$28.28 12-month price target on the company, via a total of 15 analysts, with 5 analysts having strong buy ratings and the other 10 having buy ratings. The street high comes from BTIG with a C$34 price target, and the lowest target comes in at C$24.

13 analysts have revenue estimates for the second quarter. The mean between all 13 is $307.41 million; this number has been revised slightly downwards from $295.79 million at the start of the year. Curaleaf has guided for revenue to come in between $305 – $315 million this quarter. The street high is $314.13 million while the lowest sits at $295.56 million.

Ten analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 51.03%, with this number being flat since the start of the year. Street high goes to MKM Partners with a 58.9% estimate and the lowest sits at 43%.

Onto EBITDA estimates, there are currently 11 analysts who have second quarter EBITDA estimates. The mean is currently $83.85 million, with this number being slightly lower at the start of the year. Street high goes to MKM Partners with a $94.40 million EBITDA estimate and the lowest being a $76.32 million estimate.

---

Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.